You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

monoclonal anti-CD19 antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia

Recruiting
  • Recurrent B Acute Lymphoblastic Leukemia
  • +3 more
  • Blinatumomab
  • +2 more
  • New Haven, Connecticut
  • +6 more
Jul 9, 2022

Chronic Lymphocytic Leukemia Trial in Portland (drug, procedure, biological, other)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jul 12, 2023

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Duarte (procedure, biological, drug)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Biospecimen Collection
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 30, 2023

Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder Trial

Not yet recruiting
  • Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
  • Polymorphic Post-Transplant Lymphoproliferative Disorder
  • Biopsy
  • +5 more
  • New Brunswick, New Jersey
  • +2 more
Mar 23, 2023

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +7 more
  • Blinatumomab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +11 more
  • Biopsy
  • +5 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Non-Hodgkin Lymphoma Trial in Columbus (Biospecimen Collection, Computed Tomography, Positron Emission Tomography)

Recruiting
  • Non-Hodgkin Lymphoma
  • Biospecimen Collection
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Jan 13, 2023

Coronavirus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Trial in United States

Terminated
  • Coronavirus Disease 2019 (COVID-19)
  • Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
  • anti-CD14
  • +2 more
  • Torrance, California
  • +13 more
Mar 24, 2022

Relapsed/Refractory Large B Cell Lymphoma, Relapsed/Refractory Follicular Lymphoma Trial in United States (genetic, biological,

Active, not recruiting
  • Relapsed/Refractory Large B Cell Lymphoma
  • Relapsed/Refractory Follicular Lymphoma
  • ALLO-501
  • +3 more
  • Gilbert, Arizona
  • +7 more
May 25, 2022

COVID, ARDS, Human, Ards Trial in Milano (IC14, a mAb against CD14)

No longer available
  • COVID
  • +3 more
  • IC14, a monoclonal antibody against CD14
  • Milano, Italy
    IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffael
Jun 15, 2021

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell Trial in Najing (Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Lymphoma, T-Cell
  • Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection
  • Najing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Sep 26, 2022

Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma

Not yet recruiting
  • Double-Expressor Lymphoma
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 27, 2022

Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia Trial in

Terminated
Has Results
  • Philadelphia Chromosome Negative
  • +2 more
  • Blinatumomab
  • +11 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 3, 2022

Primary Immune Thrombocytopenia (ITP) Trial in Tianjin (TPO-RAs, TPO-RAs combining anti-CD 20 mAb)

Not yet recruiting
  • Primary Immune Thrombocytopenia (ITP)
  • TPO-RAs
  • TPO-RAs combining anti-CD 20 monoclonal antibody
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Feb 7, 2023

Recurrent DLBCL, Refractory DLBCL Trial in Sacramento (Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Chimeric Antigen Receptor T-Cell Therapy
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Mar 8, 2022

Primary Membranous Nephropathy Trial in Beijing (B007)

Not yet recruiting
  • Primary Membranous Nephropathy
  • Beijing, China
    Peking university first hospital
Dec 20, 2022

Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)

Recruiting
  • Safety and Efficacy
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Sep 27, 2023

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Trial in Seattle (procedure, drug, biological)

Not yet recruiting
  • B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
  • Bone Marrow Aspiration and Biopsy
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

DLBCL Trial in Houston (Acalabrutinib, Cyclophosphamide, Doxorubicin Hydrochloride)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 10, 2022

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +5 more
  • Blinatumomab
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 1, 2022

Recurrent Glioblastoma, Refractory Glioblastoma Trial in Duarte (IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory

Recruiting
  • Recurrent Glioblastoma
  • Refractory Glioblastoma
  • IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Oct 29, 2021

SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)

Recruiting
  • SLE (Systemic Lupus)
  • +4 more
  • CD19 targeted CAR-T cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Sep 25, 2023

NSCLC Stage IV Trial (HLX26, Serplulimab, Pemetrexed)

Not yet recruiting
  • NSCLC Stage IV
  • (no location specified)
Mar 15, 2023

Non-Malignant Tumor Trial in Seattle (biological, drug, radiation, procedure)

Recruiting
  • Non-Malignant Neoplasm
  • Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 29, 2022